A life science venture capital firm with strong China expertise and global capabilities discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in US and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market. The firm is open to global companies, typically allocating between $250k-1.5M USD. The firm can act as a lead investor and co-investor.

In terms of life science, the firm invests in cancer-focused digital health companies, however, does not invest in drugs, therapeutics, medical devices, and technologies that require FDA approval.

The firm does not have specific management team requirements and does not require to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading European venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to patients, with a focus on indications with high unmet needs. The firm has a diverse international team in Spain that is driven by science, with the ambition to transform capital into medical breakthroughs. The firm has over €400M million in assets under management through its three funds. The investments typically range from 5 million to 20 million, including additional capital for follow-on investments.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new family office fund of a successful hedge fund manager focused on private investments has multiple offices in the US. Due to the single LP structure of the fund, it can be very flexible in terms of investment size and stage. The firm is open to working with companies in the seed, series A, and series B stage with the majority of investments falling in the $500k-2.5M range. The firm also has the ability to allocate $5M or more in situations where they find the opportunity particularly compelling. The firm is capable of both acting as a lead and co-investor, and is primarily focused on companies throughout North America but has exposure to Europe and Asia as well.

The firm has a focus on vertically integrated platforms and software/”software x hardware” systems. Specifically, the firm is interested in AI-enabled drug discovery platforms, lab automation, diagnostics and data collection, and clinical trials management software. The firm is generally agnostic in terms of both stage of development and indication area but is most interested in early stage, highly innovative biotech companies.

The firm is looking for privately held companies with experienced management teams and a product/service with a large addressable market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Frazier Healthcare Ventures was founded in 1991 and is based in Seattle, WA.  The firm has $2.2 billion of assets under management, and closed a new $525 million fund in 2016.  Frazier currently has two investment strategies; growth-stage investments in healthcare and pharma service providers (these investments focus on companies with $5-30m EBITDA), and venture-stage investments in life science companies.  Frazier’s venture allocations have initial sizes of $5m or higher, with the potential for allocations of up to $20m over the life of an investment.  While Frazier primarily invests in companies based in or with significant operations in the USA and/or Canada, the firm will also consider opportunities in Europe.  In addition to growth and venture-stage investments, Frazier also engages in company creation.  The firm is a lead investor in most of its deals.

Frazier Life Sciences only invests in therapeutics, with a focus on asset-based companies. Frazier typically prefers to invest in companies with products which are 6-18 months away from bringing a product candidate into Phase I clinical trials, but may consider investing in assets that are earlier or later than that. The firm invests in all therapeutic areas and all modalities.

Frazier Healthcare Ventures has no fixed requirements for companies or management teams, but looks for strong teams that lead companies that can make use of over $10m in capital; companies with smaller capital needs are not of interest. Frazier can invest in both privately-held and public life science companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established, early-stage venture fund backed by a sole strategic LP and managed by leading VC firms is actively seeking new investment opportunities. The LP’s decision to invest in the fund reflects the company’s vision of developing disruptive, cost-saving healthcare solutions, which closely matches the vision of the investment team. The firm focuses on US, Europe, and Israel-based companies.

The firm is dedicated to early-stage investing in novel, disruptive medtech and digital health companies that can transform hospital care to lower-cost settings such as the home and health clinics. Areas of particular interest include non-invasive therapeutic medical devices, monitoring technologies for effective chronic disease management and preventative technologies, and is open to devices of all regulatory pathways.

The firm is looking for technologies supported by strong clinical hypotheses that can cost-effectively address large problems in the current healthcare system. The firm is open to working with all kinds of management teams in the US, Europe or Israel. The firm has access to an international network and resources that can be leveraged to support company growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital firm based in the US is focused on early and growth-stage biotech and pharma companies. The firm has more than $350M assets under management. Initial investments typically range from $2M-$20M and are usually in the form of equity, but may use convertible notes in select situations. The firm looks to take a meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm focuses on therapeutic companies within the biotech sector. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies developing assets with unique mechanisms of action that address unmet medical needs. The firm typically invests in companies ranging from late preclinical to Phase 2 clinical trials stage. The firm does NOT invest in diagnostic, device, digital health, or healthcare IT companies.

The firm has no strict company or management team requirements, but usually requires a board seat along with an investment to allow for active participation and collaboration with the company during development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.